- 英文名称
- Ensitrelvir
- 分子式
- C22H17ClF3N9O2
- 分子量
- 531.88
- 中文别名
- (E)-6-((6-氯-2-甲基-2H-吲唑-5-基)亚氨基)-3-((1-甲基-1H-1,2,4-三唑-3-基)甲基)-1-(2,4,5-三氟苄基)-1,3,5-三嗪烷-2,4-二酮; (6E)-6-[(6-氯-2-甲基-2H-吲唑-5-基)亚氨基]二氢-3-[(1-甲基-1H-1,2,4-三唑-3-基)甲基]-1-[(2,4,5-三氟苄基)甲基]-1,3,5-三嗪烷-2,4(1H,; 义恩赛特韦; 化合物ENSITRELVIR; 恩斯特韦中间体; 恩斯特韦; (E)-6-((6-Chloro-2-methyl-2H-indazol-5-yl)imino)-3-((1-methyl-1H-1,2,4-triazol-3-yl)methyl)-1-(2,4,5-trifluorobenzyl)-1,3,5-triazinane-2,4-dione; 1,3,5-Triazine-2,4(1H,3H)-dione, 6-[(6-chloro-2-methyl-2H-indazol-5-yl)imino]dihydro-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-1-[(2,4,5-trifluorophenyl)methyl]-, (6E); 1,3,5-Triazine-2,4(1H,3H)-dione, 6-[(6-chloro-2-methyl-2H-indazol-5-yl)imino]dihydro-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-1-[(2,4,5-trifluorophenyl)methyl]-, (6E)-; S-217622
- 用途
- 作为新冠药物恩赛特韦(Ensitrelvir)的有效成分富马酸恩赛特韦的核心结构;是一种具有口服活性的非共价、非肽SARS-CoV-2 3CL蛋白酶抑制剂;用于治疗12岁以上轻中症新冠病毒感染者,每天一次,服用5天,可快速缓解发热、流鼻涕、咽痛、咳嗽等症状